V8 Peptides — Engineered Performance
Research Library
Ordering BPC-157 and TB-500: Lab Planning Guide
BPC-157Guide

Ordering BPC-157 and TB-500: Lab Planning Guide

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

How should a lab plan an order of BPC-157 and TB-500? Decide first whether the design needs the two peptides as independent variables (separate vials) or only as a fixed pair (the co-lyophilized Wolverine Stack, 10 mg of each in one 20 mg vial). Note that V8's TB-500 is the synthetic 17–23 fragment of thymosin β4 (Ac-LKKTETQ, about 889 Da), not the 43-residue full-length protein, which matters for any comparison with the thymosin β4 literature. Calculate total moles from stated masses, plan single-use aliquots, check lots against the COA library on receipt, and log everything. Both are supplied for laboratory research use only.

Labs studying tissue-response pathways sometimes want BPC-157 and TB-500 in the same experiment. The ordering decision looks trivial, but it fixes the experiment's flexibility, its arithmetic and its documentation burden. This guide walks through the planning decisions, uses only facts from the live product pages, and keeps the discussion at the level of study design and handling. For the biological rationale of the pairing, see BPC-157 vs TB-500 and the combination research article; for the pillars see the BPC-157 overview and the TB-500 research overview. No prices are discussed. All material is for laboratory research use only.

What each product page says

The facts below come from the live product pages.

ItemBPC-157TB-500Wolverine Stack
PageBPC-157TB-500Wolverine Stack
Size10 mg10 mg10 mg + 10 mg in one co-lyophilized vial (20 mg total)
Purity≥98% (HPLC)≥98% (HPLC)≥98% (HPLC)
IdentityGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-ValAc-Leu-Lys-Lys-Thr-Glu-Thr-Gln, formula C38H68N10O14Reported on the certificate, where published
FormLyophilized powderLyophilized powderLyophilized powder
Storage lineRefrigerate at 2–8 °C; −20 °C for long-term. Protect from heat, moisture and light.
ContainerSealed clear glass research vial

The BPC-157 page describes a synthetic pentadecapeptide for laboratory research use only, with research areas in tissue-response pathway models, extracellular-matrix signaling, connective-tissue biology and gastrointestinal research models. The TB-500 page describes the synthetic 17–23 fragment of thymosin β4 studied for actin regulation, cell migration and tissue-response mechanisms.

The identity point that changes the literature search

The name "TB-500" is used loosely. Thymosin β4 itself is a 43-residue, highly conserved protein that is the main G-actin-sequestering molecule in many cells, and reviews describe a wide range of functions for β-thymosins (Huff et al., 2001; Goldstein et al., 2005). The TB-500 sold on the V8 page is not the full protein: it is the seven-residue fragment Ac-LKKTETQ, residues 17–23, a fragment of thymosin β4. A study that tested thymosin β4 together with a synthetic peptide containing its actin-binding domain in dermal wound models in diabetic and aged mice (Philp et al., 2003) shows why the distinction is relevant: the full protein and the fragment are separate molecules, and results for one should not be transferred to the other without a stated reason. When searching, use the exact name and sequence on the certificate as the key. A note on the distinction is also in TB-500 vs thymosin beta-4.

For BPC-157, the research literature is concentrated in a small number of groups, and the reviews in the area, for example on the brain–gut axis and the pentadecapeptide (Sikiric et al., 2016), address its theoretical and practical implications in the context of the brain–gut axis. The compound and its sequence are as the product page states; the planning point is that the preclinical record is narrower in provenance than the volume of publications suggests, so replication in house with proper controls matters.

Separate vials or a blend: the design question

The choice is mostly about what must be independent in the experiment.

  • Separate vials let the ratio vary, let each peptide be omitted to make single-agent arms, and let each be stored and aliquoted independently. They require two reconstitutions and two sets of records.
  • The co-lyophilized Wolverine Stack fixes the ratio at equal masses and removes one source of pipetting error, but it cannot yield single-agent arms from the same vial and cannot change the ratio. The blend vial is the logical choice only when the design asks about that exact pair at that exact ratio.

The point about equal masses has a molar consequence. BPC-157 has a molar mass of roughly 1,420 g/mol when calculated from its sequence, and TB-500 is about 889 g/mol. Ten milligrams of each therefore contain about 7.0 µmol of BPC-157 and about 11.3 µmol of TB-500, a molar ratio of roughly 1 to 1.6. A design stated in molar terms cannot use the blend without recognizing that ratio. The reasoning for blends in general is in peptide blends and research stacks, and the specific listing in GLOW vs KLOW vs Wolverine stack comparison.

Planning quantities with formulas

The planning arithmetic is the same for any peptide: moles = mass ÷ molar mass, concentration = moles ÷ volume, and total requirement = per-well or per-animal amount × number of units × number of repeats × a margin. Do the calculation in molar units, because masses of peptides with different molar masses are not comparable. The margin should cover the dead volume in tips and tubes, adsorption losses, and one failed run. The reconstitution calculator converts mass and diluent volume to concentration; this article deliberately gives no per-product volume tables, so each lab works from its own design numbers.

Planning stepQuestionRecord
Define armsSingle agents, pair, vehicle, untreated?Arm list with n per arm
Define the unit of exposurePer well, per animal or per assayAmount per unit, as written in the protocol
Convert to molesMass ÷ molar mass for each peptideMolar mass used, and its source
Add marginDead volume, adsorption, repeatsMargin and reason
Match to vial sizesFewest vials that cover the totalVial count; remaining stock

Receiving checks

On arrival, check the seal, the label, and the lot number, and compare the lot with the COA library. The BPC-157 and stack pages state that the lot certificate is published online; the TB-500 page lists the certificate fields. Where a certificate is not listed for a lot, record that. How to read a COA explains the fields, and BPC-157 and TB-500 third-party testing covers independent verification. Log the date, the condition on arrival and the storage location. Store sealed vials as the page states, and let each reach room temperature before opening.

A clear glass vial gives no light protection, so keep vials boxed. A freeze-dried cake that has broken up in transit is cosmetic; a solid that looks wet, collapsed or discolored should be noted before use, as described in peptide vial appearance: what is normal.

Reconstitution and aliquots

Reconstitution technique for lyophilized peptides is covered in how to reconstitute a lyophilized peptide and for the blend in BPC-157/TB-500 blend reconstitution. For planning purposes, the main points are: decide the stock concentration from the design, prepare the stock once, divide it into single-use portions, and avoid repeated freeze–thaw cycles. General adsorption of peptides to plastic is a recognized source of loss, and the choice of plasticware is discussed in the peptide literature (Goebel-Stengel et al., 2011); low-binding tubes and few transfers keep the loss small. Stability of stored peptide solutions in general is reviewed by Manning and colleagues (2010). No validated shelf life is published for these specific products after reconstitution, so plan the experiment series to use each aliquot promptly.

Common planning errors

Four mistakes recur. The first is comparing the two peptides by mass instead of by moles, which hides a molar difference of about 1.6-fold. The second is handling a pre-mixed vial as two independent variables: because both peptides are in one vial, any effect seen belongs to the pair, and no statement about either alone can be drawn from it. The third is searching the literature under the name TB-500 and applying full-length thymosin β4 results to a seven-residue fragment. The fourth is skipping the vehicle arm: the diluent, the plasticware and the handling steps are part of the exposure, so a vehicle-only group prepared in the same way is needed to interpret any difference. Each of these is cheap to prevent on paper and expensive to repair after the animals or cultures have been used.

A fifth, quieter error is to plan the quantity from a single run and then discover that the repeat needed a fresh vial. Writing the number of repeats into the requirement at the start, and ordering the vial count that covers them, keeps the whole series on one lot, which is itself a design advantage because lot-to-lot differences then cannot be mistaken for exposure effects.

Documentation worth keeping

A one-page record per order is enough: the source page and date, the lot numbers, the certificate status for each lot, the molar masses used, the planned and actual stock concentrations, the aliquot map and the storage location. When an experiment later produces a surprising result, this record is the first thing to examine. For the library of related material, browse the shop.

Frequently asked questions

Is V8's TB-500 the full thymosin β4 protein?

No. The product page describes it as the synthetic 17–23 fragment of thymosin β4, Ac-LKKTETQ, about 889 Da. Full-length thymosin β4 is a 43-residue protein.

What is in the Wolverine Stack vial?

BPC-157 10 mg and TB-500 10 mg co-lyophilized in a single vial, 20 mg total, according to the product page.

When should I buy separate vials instead of the blend?

When the design needs single-agent arms, a variable ratio, or independent storage and aliquoting of each peptide.

What is the molar ratio in the blend?

Calculated from the stated 10 mg of each, using about 1,420 g/mol for BPC-157 and about 889 g/mol for TB-500, it is roughly 1 BPC-157 to 1.6 TB-500. Verify the molar masses against the certificate.

How should vials be stored on arrival?

The product pages state: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

How do I find the certificate for my lot?

Compare the lot number on the vial with the COA library. Record the result, including when no certificate is listed.

How do I calculate the amount I need?

Work in moles: mass divided by molar mass, then concentration as moles divided by volume. Total requirement is per-unit amount times units times repeats, plus margin.

Do the product pages give a shelf life after reconstitution?

No. No validated shelf life is published. Divide stocks into single-use portions and use them promptly.

Why use low-binding plasticware?

Peptides can adsorb to plastic and glass, and the proportional loss is greatest in dilute solutions.

Does this article recommend an amount to use in experiments?

No. It covers planning arithmetic and handling. Study parameters come from a lab's own design and the primary literature.

Research-use statement

All material discussed here is supplied for laboratory research use only; not for human consumption, and not a drug, food or cosmetic.

Related reading: BPC-157 Certificate of Analysis: A Line-by-Line Read, BPC-157 Introduction: How to Read the Research.

References

  1. GOLDSTEIN A, HANNAPPEL E, KLEINMAN H. Thymosin β: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004
  2. Huff T, Müller CS, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. The International Journal of Biochemistry & Cell Biology. 2001;33(3):205-220. doi:10.1016/S1357-2725(00)00087-X
  3. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin β4 and a synthetic peptide containing its actin‐binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regeneration. 2003;11(1):19-24. doi:10.1046/j.1524-475x.2003.11105.x
  4. Malinda KM, Kleinman HK, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, et al. Thymosin β4 Accelerates Wound Healing. Journal of Investigative Dermatology. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
  5. Sikiric P, Seiwerth S, Rucman R, Kolenc D, Batelja Vuletic L, Drmic D, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. CN. 2016;14(8):857-865. doi:10.2174/1570159X13666160502153022
  6. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
  7. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: An Update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.